MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy.

Although IFN-γ-treated SUIT-2 cells (MHCII-positive) induced a weak proliferation (Proliferation index = 1.2) as well as some increase in IFN-γ (from 130.5 pg/mL to 931.8 pg/mL, CD8+ T-cells alone vs CD8+ T-cells + IFN-γ-treated Suit-2), the difference did not reach statistical significance.

also in 111,027 other papers